高敏肌钙蛋白检测的患者选择与心肌梗死诊断:前瞻性队列研究
该前瞻性研究在英美急诊科连续纳入8500例患者,测量高敏肌钙蛋白I并独立裁定1型或2型心肌梗死或心肌损伤。英国未选择患者(n=1054)中肌钙蛋白升高13.7%,1型心肌梗死患病率1.6%,阳性预测值11.8%(95%CI 7.0%–18.2%)。英国临床医生选择检测的患者(n=5815)患病率14.5%、阳性预测值59.7%(57.0%–62.2%);美国选择检测的患者(n=1631)患病率4.2%、阳性预测值16.4%(13.0%–20.3%)。阳性预测值在胸痛、心电图缺血及有缺血性心脏病史的患者中最高。
要点
- 英国未选择急诊患者中肌钙蛋白升高率13.7%(144/1054),1型心肌梗死患病率仅1.6%(17/1054),阳性预测值11.8%(95%CI 7.0%–18.2%)。
- 英国临床医生选择检测的患者阳性预测值59.7%(95%CI 57.0%–62.2%),远高于未选择患者的11.8%。
- 美国临床医生选择检测的患者阳性预测值16.4%(95%CI 13.0%–20.3%),患病率4.2%(68/1631)。
- 阳性预测值在胸痛、心电图缺血及有缺血性心脏病史的患者中最高。
- 广泛或无临床评估前检测时,肌钙蛋白升高常见且主要反映心肌损伤而非心肌梗死。
适用人群与场景
- 英国未选择急诊患者(n=1054)、英国临床医生选择检测的急诊患者(n=5815)、美国临床医生选择检测的急诊患者(n=1631),均为连续纳入。
- 研究在英美二级和三级医院急诊科进行。
研究设计与关键结果
- 研究类型:前瞻性研究,三个独立连续急诊患者人群,共8500例,测量高敏肌钙蛋白I,独立裁定1型或2型心肌梗死或心肌损伤。
- 英国未选择患者:肌钙蛋白升高13.7%(144/1054),1型心肌梗死患病率1.6%(17/1054),阳性预测值11.8%(95%CI 7.0%–18.2%)。
- 英国临床医生选择检测患者:患病率14.5%(843/5815),阳性预测值59.7%(95%CI 57.0%–62.2%)。
- 美国临床医生选择检测患者:患病率4.2%(68/1631),阳性预测值16.4%(95%CI 13.0%–20.3%)。
- 阳性预测值在胸痛、心电图缺血及有缺血性心脏病史的患者中最高。
证据类型、等级与局限
- 证据类型:前瞻性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 临床医生选择检测的患者中肌钙蛋白升高的阳性预测值高于未选择患者,提示检测前临床评估影响心肌梗死诊断概率。
- 广泛或无临床评估前检测时,肌钙蛋白升高主要反映心肌损伤而非心肌梗死。
- 阳性预测值在胸痛、心电图缺血及有缺血性心脏病史的患者中最高。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Objective To evaluate how selection of patients for high sensitivity cardiac troponin testing affects the diagnosis of myocardial infarction across different healthcare settings.Design Prospective study of three independent consecutive patient populations presenting to emergency departments.Setting Secondary and tertiary care hospitals in the United Kingdom and United States.Participants High sensitivity cardiac troponin I concentrations were measured in 8500 consecutive patients presenting to emergency departments: unselected patients in the UK (n=1054) and two selected populations of patients in whom troponin testing was requested by the attending clinician in the UK (n=5815) and the US (n=1631). The final diagnosis of type 1 or type 2 myocardial infarction or myocardial injury was independently adjudicated.Main outcome measures Positive predictive value of an elevated cardiac troponin concentration for a diagnosis of type 1 myocardial infarction.Results Cardiac troponin concentrations were elevated in 13.7% (144/1054) of unselected patients, with a prevalence of 1.6% (17/1054) for type 1 myocardial infarction and a positive predictive value of 11.8% (95% confidence interval 7.0% to 18.2%). In selected patients, in whom troponin testing was guided by the attending clinician, the prevalence and positive predictive value were 14.5% (843/5815) and 59.7% (57.0% to 62.2%) in the UK and 4.2% (68/1631) and 16.4% (13.0% to 20.3%) in the US. Across both selected patient populations, the positive predictive value was highest in patients with chest pain, with ischaemia on the electrocardiogram, and with a history of ischaemic heart disease.Conclusions When high sensitivity cardiac troponin testing is performed widely or without previous clinical assessment, elevated troponin concentrations are common and predominantly reflect myocardial injury rather than myocardial infarction. These observations highlight how selection of patients for cardiac troponin testing varies across healthcare settings and markedly influences the positive predictive value for a diagnosis of myocardial infarction.
参考来源
- Shah ASV, Sandoval Y, Noaman A, et al. Patient selection for high sensitivity cardiac troponin testing and diagnosis of myocardial infarction: prospective cohort study. BMJ. 2017. PMID: 29114078. doi:10.1136/bmj.j4788
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。